ISAM - The International Society for Aerosols in Medicine
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through
the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient.
Our journal coverage:
Pulmonary drug delivery
Aerosol drug delivery devices (ADDD) as pressurised Metered-Dose-Inhalers (pMDI), Dry-Powder-Inhaler (DPI), Liquid-Metered-Inhalers (MLI), nebulizers using jet, vibrating mesh or soft-mist technologies
New connected inhalation devices and novel technologies
Usability of inhalation devices and use errors
In vitro characterisation of inhalation devices
Airway reactivity and asthma treatment
Asthma pathopysiology
Asthma management
Asthma control
Treatment of asthma and therapeutics
Inhalation devices in asthma
Inhalation of particles and gases in the respiratory tract
Deposition mechnisms
Deposition parameters
Aerosol characterization
Regional deposition
Imaging aerosol deposition
Pharmacokinetics
Deposition models
Regional deposition targeting
Carrier gases and effects on delivery
Respiratory disease and effect on particle deposition
Toxic effects of inhaled agents
Mechanisms of absorbance and clearance
Preclinical safety of inhaled agents (small molecules, peptides, human or animal derived proteins)
Toxic effects of environmental or occupational aerosol exposure
Effects from airway exposure to e-cigarrette or conventional cigarette aerosols
Aerosols as tools for studying basic physiologic phenomena
Mechanisms of aerosol formation by breathing
Physiological and pathophysiological effects on aerosol deposition
Lung macrophage function evaluated by magnetic aerosols
Open Access Publishing: Members of ISAM are entitled to an optional, discounted APC fee, a 25% savings off the full APC rate. ISAM members will continue to receive a 25% discounted off prevailing
APC rate.
Page Charges Discount: Members of ISAM who are entitled to a discount rate on page charges. The regular page charge rate for the journal is (date Jan 23, 2022) $65 per page, ISAM member pay $30, a 54% discount.
The Official Journal of the International Society for Aerosols in Medicine
The Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery
of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized
drugs in the intubated patient.
Coverage
Pulmonary drug delivery
Airway reactivity and asthma treatment
Inhalation of particles and gases in the respiratory tract
Toxic effects of inhaled agents
Aerosols as tools for studying basic physiologic phenomena
Journal Impact Factor and Citation Score
The Journal of Aerosol Medicine and Pulmonary Drug Delivery impact factor increased by 21% over the 2020 impact factor. The Journals CiteScore increased to 5.1.
The impact factor, also denoted as Journal impact factor (JIF), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal.
Latest Impact Factor (2022) is 3.440
Editors
Editor-in-Chief: Thomas O'Riordan, MD, MPH, Vice President US Medical and Head of Respiratory Therapeutic Area GSK, Philadelphia, Pennsylvania, USA
Founding Editor: Gerald C. Smaldone, MD, PhD, Pulmonary, Critical Care and Sleep Division, School of Medicine, State University of New York at Stony Brook
Associate Editor: Tim Corcoran, PhD, Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh
International Editorial Board: 37 members
Indexed and Abstracted in MEDLINE; PubMed; PubMed Central; Current Contents®/Clinical Medicine; Science Citation Index Expanded; Journal Citation Reports/Science Edition; Prous Science Integrity®; EMBASE/Excerpta Medica; Scopus;
Chemical Abstract; ProQuest databases; BenchSci
Business Communication
Business communications and advertising inquiries should be addressed to the publisher Mary Ann Liebert, Inc.
Sample Articles
A Dose-Ranging Study of Epinephrine Hydrofluroalkane Metered-Dose Inhaler (Primatene® MIST) in Subjects with Intermittent or Mild-to-Moderate Persistent Asthma
Edward M. Kerwin, Donald P. Tashkin, Thomas R. Murphy, George W. Bensch, Tony Marrs, Mary Z. Luo, and Jack Y. Zhang
Published Online:28 Jul 2020
https://doi.org/10.1089/jamp.2019.1558
Background: Two sequential single-dose crossover dose-ranging studies were performed to evaluate the clinical efficacy and safety profile of epinephrine hydrofluroalkane (HFA) metered-dose inhaler (MDI) formulation at various doses in subjects with asthma.
Methods: In these multicenter, multiarm, double-blinded, or evaluator-blinded studies, subjects were randomized to receive the epinephrine HFA (Primatene® MIST HFA) MDI medication at doses ranging from 90 to 440 μg/dose, as well as
to a placebo (PLA) control and an active control of epinephrine CFC (chlorofluorocarbon) MDI (Primatene® MIST CFC) at 220 μg/inhalation. Results: Spirometry testing for FEV1 (Forced Expiratory Volume in one second) demonstrated statistically
significant improvements over PLA for epinephrine HFA MDI at all doses above 125 μg, as the amount out of the actuator (i.e., mouthpiece). The efficacy results for epinephrine HFA MDI in the dose range of 125–250 μg were also comparable
to epinephrine CFC MDI (220 μg/inh). Safety assessments demonstrated minimal safety concerns for all treatment groups. No notable safety differences were observed between the studied doses of epinephrine HFA MDI and the active control
formulation of epinephrine CFC MDI. Conclusion: The findings indicate that epinephrine HFA MDI provided clinically significant bronchodilator efficacy with minimal safety concerns in a dose range of 125–250 μg. These findings confirmed
the optimal treatment doses of 125–250 μg that were appropriate for use in longer term 12 and 26 week chronic dosing studies of epinephrine HFA MDI for patients with intermittent or mild to moderate persistent asthma. Clinical trials
registration number: NCT01025648.
The Size Distribution of Droplets in the Exhaled Breath of Healthy Human Subjects
View article Tools Share Abstract Droplets carried in exhaled breath may carry microorganisms capable of transmitting disease over both short and long distances. The size distribution of such droplets will influence the type of organisms
that may be carried as well as strategies for controlling airborne infection. The aim of this study was to characterize the size distribution of droplets exhaled by healthy individuals. Exhaled droplets from human subjects performing
four respiratory actions (mouth breathing, nose breathing, coughing, talking) were measured by both an optical particle counter (OPC) and an analytical transmission electron microscope (AEM). The OPC indicated a preponderance of
particles less than 1 μ, although larger particles were also found. Measurements with the AEM confirmed the existence of larger sized droplets in the exhaled breath. In general, coughing produced the largest droplet concentrations
and nose breathing the least, although considerable intersubject variability was observed.
